BofA lowered the firm’s price target on Krystal Biotech (KRYS) to $192 from $193 and keeps a Buy rating on the shares. The firm, which continues to see growth potential for Vyjuvek with launches outside of the U.S. this year, updated its model and slightly lowered near-term Vyjuvek revenues while increasing SG&A costs to reflect hiring of additional sales reps.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Optimistic Buy Rating for Krystal Biotech Driven by Innovative Gene Therapy KB801 for Neurotrophic Keratitis
- Krystal Biotech price target raised to $176 from $155 at Citi
- Cautious Optimism for Krystal Biotech’s KB801 Amidst Uncertain Efficacy Data
- Promising Market Potential and Innovative Approach Drive Buy Rating for Krystal Biotech’s Gene Therapy KB801
- Krystal Biotech Begins Phase 1/2 Trial for KB801